| (-)-epigallocatechin 3-gallate | multiple interactions | EXP | | 6480464 | [potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of MAP1LC3B mRNA | CTD | PMID:22079256 |
| 17alpha-ethynylestradiol | affects expression | ISO | RGD:1551009 | 6480464 | Ethinyl Estradiol affects the expression of MAP1LC3B mRNA | CTD | PMID:17555576 |
| 17alpha-ethynylestradiol | multiple interactions | ISO | RGD:1551009 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of MAP1LC3B mRNA | CTD | PMID:17942748 |
| 17alpha-ethynylestradiol | decreases expression | ISO | RGD:1551009 | 6480464 | Ethinyl Estradiol results in decreased expression of MAP1LC3B mRNA | CTD | PMID:17942748 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:621315 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MAP1LC3B mRNA | CTD | PMID:16054898 more ... |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:1551009 | 6480464 | Tetrachlorodibenzodioxin affects the expression of MAP1LC3B mRNA | CTD | PMID:21570461 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:621315 | 6480464 | Tetrachlorodibenzodioxin affects the expression of MAP1LC3B mRNA | CTD | PMID:22298810 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:621315 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MAP1LC3B mRNA | CTD | PMID:18796159 more ... |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:621315 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of MAP1LC3B mRNA | CTD | PMID:18465118 more ... |
| 2,3,7,8-tetrachlorodibenzodioxine | decreases expression | ISO | RGD:1551009 | 6480464 | Tetrachlorodibenzodioxin results in decreased expression of MAP1LC3B mRNA | CTD | PMID:19770486 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:1551009 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in decreased expression of MAP1LC3B mRNA | CTD | PMID:17942748 |
| 2-deoxy-D-glucose | multiple interactions | EXP | | 6480464 | ATG7 protein promotes the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein]; more ... | CTD | PMID:20593179 |
| 2-deoxy-D-glucose | increases prenylation | EXP | | 6480464 | Deoxyglucose results in increased prenylation of MAP1LC3B protein | CTD | PMID:20593179 |
| 3-methyladenine | multiple interactions | ISO | RGD:1551009 | 6480464 | 3-methyladenine inhibits the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein alternative form] | CTD | PMID:21325019 |
| 3-methyladenine | multiple interactions | EXP | | 6480464 | 3-methyladenine inhibits the reaction [E platinum results in increased expression of MAP1LC3B protein]; more ... | CTD | PMID:22322152 |
| 3-methyladenine | multiple interactions | EXP | | 6480464 | 3-methyladenine inhibits the reaction [vorinostat results in increased expression of MAP1LC3B protein modified form] | CTD | PMID:20962572 |
| 3-methyladenine | multiple interactions | ISO | RGD:621315 | 6480464 | 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein modified form] | CTD | PMID:18640276 |
| 3-methyladenine | decreases expression | ISO | RGD:1551009 | 6480464 | 3-methyladenine results in decreased expression of MAP1LC3B mRNA | CTD | PMID:21681844 |
| 3H-1,2-dithiole-3-thione | decreases expression | ISO | RGD:621315 | 6480464 | 1,2-dithiol-3-thione results in decreased expression of MAP1LC3B mRNA | CTD | PMID:19162173 |
| 4,4'-diaminodiphenylmethane | decreases expression | ISO | RGD:1551009 | 6480464 | 4,4'-diaminodiphenylmethane results in decreased expression of MAP1LC3B mRNA | CTD | PMID:18648102 |
| 4-hydroxynon-2-enal | increases expression | ISO | RGD:1551009 | 6480464 | 4-hydroxy-2-nonenal results in increased expression of MAP1LC3B mRNA | CTD | PMID:19191707 |
| 4-hydroxyphenyl retinamide | increases expression | EXP | | 6480464 | Fenretinide results in increased expression of MAP1LC3B mRNA | CTD | PMID:16671099 |
| 5-aza-2'-deoxycytidine | multiple interactions | EXP | | 6480464 | decitabine inhibits the reaction [sodium arsenite results in increased expression of MAP1LC3B protein] | CTD | PMID:19577553 |
| 5-fluorouracil | affects response to substance | EXP | | 6480464 | MAP1LC3B protein affects the susceptibility to Fluorouracil | CTD | PMID:15548681 |
| ammonium chloride | affects expression | ISO | RGD:621315 | 6480464 | Ammonium Chloride affects the expression of MAP1LC3B mRNA | CTD | PMID:16483693 |
| benzo[a]pyrene | multiple interactions | ISO | RGD:1551009 | 6480464 | [Benzo(a)pyrene co-treated with XPA gene mutant form co-treated with TRP53 gene mutant form] results in increased expression of MAP1LC3B mRNA | CTD | PMID:21715664 |
| benzo[a]pyrene | increases expression | ISO | RGD:1551009 | 6480464 | Benzo(a)pyrene results in increased expression of MAP1LC3B mRNA | CTD | PMID:22228805 |
| benzo[a]pyrene | increases expression | EXP | | 6480464 | Benzo(a)pyrene results in increased expression of MAP1LC3B mRNA | CTD | PMID:22316170 |
| beta-lapachone | multiple interactions | EXP | | 6480464 | beta-lapachone affects the localization of and results in increased metabolism of MAP1LC3B protein | CTD | PMID:21035436 |
| C60 fullerene | increases expression | ISO | RGD:621315 | 6480464 | fullerene C60 results in increased expression of MAP1LC3B mRNA | CTD | PMID:19167457 |
| cadmium atom | increases expression | ISO | RGD:1551009 | 6480464 | Cadmium results in increased expression of MAP1LC3B protein modified form | CTD | PMID:19126599 |
| cadmium dichloride | multiple interactions | ISO | RGD:1551009 | 6480464 | 3-methyladenine inhibits the reaction [Cadmium Chloride results in increased expression of MAP1LC3B protein alternative form] | CTD | PMID:21325019 |
| cadmium dichloride | increases expression | ISO | RGD:1551009 | 6480464 | Cadmium Chloride results in increased expression of MAP1LC3B protein alternative form | CTD | PMID:21325019 |
| cadmium dichloride | increases expression | ISO | RGD:621315 | 6480464 | Cadmium Chloride results in increased expression of MAP1LC3B protein alternative form | CTD | PMID:21325019 |
| celecoxib | multiple interactions | EXP | | 6480464 | MAP1LC3B mutant form promotes the reaction [[celecoxib co-treated with ABT-737] results in increased cleavage of CASP3 protein]; more ... | CTD | PMID:20104024 |
| chloroquine | increases expression | ISO | RGD:621315 | 6480464 | Chloroquine results in increased expression of MAP1LC3B mRNA | CTD | PMID:17643062 |
| ciguatoxin CTX1B | affects expression | ISO | RGD:1551009 | 6480464 | Ciguatoxins affects the expression of MAP1LC3B mRNA | CTD | PMID:18353800 |
| cisplatin | multiple interactions | EXP | | 6480464 | [Cisplatin results in increased phosphorylation of TP63 protein alternative form] which results in increased expression of MAP1LC3B protein; more ... | CTD | PMID:21191146 |
| cisplatin | increases expression | EXP | | 6480464 | Cisplatin results in increased expression of MAP1LC3B mRNA | CTD | PMID:19561079 |
| clofibrate | decreases expression | ISO | RGD:1551009 | 6480464 | Clofibrate results in decreased expression of MAP1LC3B mRNA | CTD | PMID:17585979 |
| clofibrate | increases expression | ISO | RGD:621315 | 6480464 | Clofibrate results in increased expression of MAP1LC3B mRNA | CTD | PMID:21318169 |
| cobalt dichloride | increases expression | EXP | | 6480464 | cobaltous chloride results in increased expression of MAP1LC3B mRNA | CTD | PMID:19376846 PMID:19320972 |
| cobalt dichloride | increases expression | EXP | | 6480464 | cobaltous chloride results in increased expression of MAP1LC3B mRNA | CTD | PMID:19320972 PMID:19376846 |
| copper atom | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of MAP1LC3B mRNA | CTD | PMID:20971185 |
| copper atom | multiple interactions | ISO | RGD:1551009 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MAP1LC3B mRNA | CTD | PMID:15467011 |
| copper(0) | multiple interactions | EXP | | 6480464 | [NSC 689534 binds to Copper] which results in increased expression of MAP1LC3B mRNA | CTD | PMID:20971185 |
| copper(0) | multiple interactions | ISO | RGD:1551009 | 6480464 | [ATP7A gene mutant form results in increased abundance of Copper] which results in increased expression of MAP1LC3B mRNA | CTD | PMID:15467011 |
| copper(2+) sulfate | increases expression | EXP | | 6480464 | Copper Sulfate results in increased expression of MAP1LC3B mRNA | CTD | PMID:19549813 |
| copper(II) chloride | increases expression | EXP | | 6480464 | cupric chloride results in increased expression of MAP1LC3B mRNA | CTD | PMID:17211630 |
| coumestrol | decreases expression | EXP | | 6480464 | Coumestrol results in decreased expression of MAP1LC3B mRNA | CTD | PMID:19167446 |
| cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of MAP1LC3B mRNA | CTD | PMID:20106945 |
| cyclosporin A | increases expression | EXP | | 6480464 | Cyclosporine results in increased expression of MAP1LC3B mRNA | CTD | PMID:20106945 PMID:21632981 |
| D-mannopyranose | multiple interactions | EXP | | 6480464 | Mannose inhibits the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein] | CTD | PMID:20593179 |
| dexamethasone | increases expression | ISO | RGD:621315 | 6480464 | Dexamethasone results in increased expression of MAP1LC3B mRNA | CTD | PMID:20032058 |
| dexamethasone | multiple interactions | ISO | RGD:621315 | 6480464 | Testosterone inhibits the reaction [Dexamethasone results in increased expression of MAP1LC3B mRNA] | CTD | PMID:20032058 |
| dibenzofuran | affects localization | EXP | | 6480464 | dibenzofuran affects the localization of MAP1LC3B protein | CTD | PMID:22173198 |
| dibenzofuran | increases expression | EXP | | 6480464 | dibenzofuran results in increased expression of MAP1LC3B protein modified form | CTD | PMID:22173198 |
| dibutyl phthalate | increases expression | ISO | RGD:1551009 | 6480464 | Dibutyl Phthalate results in increased expression of MAP1LC3B mRNA | CTD | PMID:21266533 |
| dioxygen | multiple interactions | EXP | | 6480464 | Oxygen deficiency inhibits the reaction [Deoxyglucose results in increased prenylation of MAP1LC3B protein] | CTD | PMID:20593179 |
| gamma-hexachlorocyclohexane | increases expression | ISO | RGD:621315 | 6480464 | Lindane results in increased expression of MAP1LC3B mRNA | CTD | PMID:17785943 |
| glutathione | increases expression | ISO | RGD:621315 | 6480464 | Glutathione deficiency results in increased expression of MAP1LC3B mRNA | CTD | PMID:15345336 |
| hydrogen peroxide | affects expression | EXP | | 6480464 | Hydrogen Peroxide affects the expression of MAP1LC3B mRNA | CTD | PMID:20044591 |
| juglone | multiple interactions | EXP | | 6480464 | juglone inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAP1LC3B protein] | CTD | PMID:20479004 |
| menadione | multiple interactions | EXP | | 6480464 | [S 3483 co-treated with Vitamin K 3] results in increased expression of MAP1LC3B protein; more ... | CTD | PMID:19819344 |
| methylphenidate | decreases expression | ISO | RGD:1551009 | 6480464 | Methylphenidate results in decreased expression of MAP1LC3B mRNA | CTD | PMID:22470460 |
| metyrapone | multiple interactions | EXP | | 6480464 | [Metyrapone co-treated with Vitamin K 3] results in increased expression of MAP1LC3B protein | CTD | PMID:19819344 |
| N-acetyl-L-cysteine | multiple interactions | EXP | | 6480464 | Acetylcysteine inhibits the reaction [vorinostat results in increased cleavage of MAP1LC3B protein] | CTD | PMID:20543569 |
| paclitaxel | increases expression | EXP | | 6480464 | Paclitaxel results in increased expression of MAP1LC3B mRNA; more ... | CTD | PMID:19815708 |
| paracetamol | increases expression | EXP | | 6480464 | Acetaminophen results in increased expression of MAP1LC3B mRNA | CTD | PMID:21420995 |
| phenobarbital | increases expression | ISO | RGD:621315 | 6480464 | Phenobarbital results in increased expression of MAP1LC3B mRNA | CTD | PMID:19162173 |
| phenobarbital | affects expression | EXP | | 6480464 | Phenobarbital affects the expression of MAP1LC3B mRNA | CTD | PMID:19159669 |
| phorbol 13-acetate 12-myristate | multiple interactions | EXP | | 6480464 | EGR1 protein promotes the reaction [PIN1 protein promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of MAP1LC3B protein]]; more ... | CTD | PMID:20479004 |
| phorbol 13-acetate 12-myristate | increases expression | EXP | | 6480464 | Tetradecanoylphorbol Acetate results in increased expression of MAP1LC3B protein | CTD | PMID:20479004 |
| pirinixic acid | increases expression | ISO | RGD:1551009 | 6480464 | pirinixic acid results in increased expression of MAP1LC3B mRNA | CTD | PMID:18445702 PMID:18301758 |
| pirinixic acid | increases expression | ISO | RGD:1551009 | 6480464 | pirinixic acid results in increased expression of MAP1LC3B mRNA | CTD | PMID:18301758 more ... |
| pirinixic acid | increases expression | ISO | RGD:1551009 | 6480464 | pirinixic acid results in increased expression of MAP1LC3B mRNA | CTD | PMID:18445702 more ... |
| pirinixic acid | increases expression | ISO | RGD:1551009 | 6480464 | pirinixic acid results in increased expression of MAP1LC3B mRNA | CTD | PMID:18445702 more ... |
| pirinixic acid | multiple interactions | ISO | RGD:1551009 | 6480464 | PPARA protein affects the reaction [pirinixic acid results in increased expression of MAP1LC3B mRNA] | CTD | PMID:21318169 |
| pirinixic acid | increases expression | ISO | RGD:1551009 | 6480464 | pirinixic acid results in increased expression of MAP1LC3B mRNA | CTD | PMID:21318169 more ... |
| quercetin | increases expression | EXP | | 6480464 | Quercetin results in increased expression of MAP1LC3B mRNA | CTD | PMID:21632981 |
| silicon dioxide | increases expression | ISO | RGD:1551009 | 6480464 | Silicon Dioxide results in increased expression of MAP1LC3B mRNA | CTD | PMID:19073995 |
| sirolimus | increases expression | EXP | | 6480464 | Sirolimus results in increased expression of MAP1LC3B mRNA; more ... | CTD | PMID:19815708 |
| sirolimus | increases expression | ISO | RGD:621315 | 6480464 | Sirolimus results in increased expression of MAP1LC3B protein modified form | CTD | PMID:18640276 |
| sirolimus | multiple interactions | ISO | RGD:621315 | 6480464 | 3-methyladenine inhibits the reaction [Sirolimus results in increased expression of MAP1LC3B protein modified form] | CTD | PMID:18640276 |
| sirolimus | affects localization | ISO | RGD:621315 | 6480464 | Sirolimus affects the localization of MAP1LC3B protein | CTD | PMID:18640276 |
| sirolimus | increases expression | ISO | RGD:1551009 | 6480464 | Sirolimus results in increased expression of MAP1LC3B mRNA | CTD | PMID:21681844 |
| sirolimus | increases expression | EXP | | 6480464 | Sirolimus results in increased expression of MAP1LC3B protein modified form | CTD | PMID:21212465 |
| tamoxifen | decreases response to substance | EXP | | 6480464 | MAP1LC3B protein results in decreased susceptibility to Tamoxifen | CTD | PMID:20479004 |
| tamoxifen | affects expression | ISO | RGD:1551009 | 6480464 | Tamoxifen affects the expression of MAP1LC3B mRNA | CTD | PMID:17555576 |
| tamoxifen | multiple interactions | EXP | | 6480464 | Tamoxifen promotes the reaction [Nelfinavir results in increased expression of MAP1LC3B protein] | CTD | PMID:20594311 |
| temozolomide | increases expression | EXP | | 6480464 | temozolomide results in increased expression of MAP1LC3B protein | CTD | PMID:19567134 |
| temozolomide | multiple interactions | EXP | | 6480464 | Thalidomide promotes the reaction [temozolomide results in increased expression of MAP1LC3B protein] | CTD | PMID:19567134 |
| tert-butyl hydroperoxide | increases expression | EXP | | 6480464 | tert-Butylhydroperoxide results in increased expression of MAP1LC3B mRNA | CTD | PMID:15336504 |
| testosterone | multiple interactions | ISO | RGD:621315 | 6480464 | Testosterone inhibits the reaction [Dexamethasone results in increased expression of MAP1LC3B mRNA] | CTD | PMID:20032058 |
| tetrachloromethane | affects expression | ISO | RGD:1551009 | 6480464 | Carbon Tetrachloride affects the expression of MAP1LC3B mRNA | CTD | PMID:17484886 |
| thalidomide | multiple interactions | EXP | | 6480464 | Thalidomide promotes the reaction [temozolomide results in increased expression of MAP1LC3B protein] | CTD | PMID:19567134 |
| trichostatin A | affects localization | EXP | | 6480464 | trichostatin A affects the localization of MAP1LC3B protein modified form | CTD | PMID:20543569 |
| trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of MAP1LC3B protein modified form | CTD | PMID:20962572 |
| trichostatin A | increases expression | EXP | | 6480464 | trichostatin A results in increased expression of MAP1LC3B mRNA | CTD | PMID:19606018 |
| trichostatin A | increases cleavage | EXP | | 6480464 | trichostatin A results in increased cleavage of MAP1LC3B protein | CTD | PMID:20543569 |
| tunicamycin | increases expression | EXP | | 6480464 | Tunicamycin results in increased expression of MAP1LC3B protein modified form | CTD | PMID:20962572 |
| tunicamycin | increases prenylation | EXP | | 6480464 | Tunicamycin results in increased prenylation of MAP1LC3B protein | CTD | PMID:20593179 |
| valproic acid | increases expression | ISO | RGD:1551009 | 6480464 | Valproic Acid results in increased expression of MAP1LC3B mRNA | CTD | PMID:21427059 |
| valproic acid | affects expression | ISO | RGD:1551009 | 6480464 | Valproic Acid affects the expression of MAP1LC3B mRNA | CTD | PMID:17963808 PMID:17292431 |
| valproic acid | affects expression | ISO | RGD:1551009 | 6480464 | Valproic Acid affects the expression of MAP1LC3B mRNA | CTD | PMID:17292431 PMID:17963808 |
| valproic acid | increases expression | ISO | RGD:621315 | 6480464 | Valproic Acid results in increased expression of MAP1LC3B mRNA | CTD | PMID:21318169 |
| valproic acid | increases expression | ISO | RGD:1551009 | 6480464 | Valproic Acid results in increased expression of MAP1LC3B mRNA | CTD | PMID:21427059 PMID:20546886 |
| valproic acid | increases expression | ISO | RGD:1551009 | 6480464 | Valproic Acid results in increased expression of MAP1LC3B mRNA | CTD | PMID:20546886 PMID:21427059 |
| zinc atom | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of MAP1LC3B mRNA | CTD | PMID:18593933 |
| zinc(0) | multiple interactions | EXP | | 6480464 | [PCI 5002 co-treated with Zinc] results in increased expression of MAP1LC3B mRNA | CTD | PMID:18593933 |